Compare Healthcare Realty Trust Incorporated Common Stock (HR) vs Oruka Therapeutics Inc. Common Stock (ORKA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Healthcare Realty Trust Incorporated Common Stock vs Oruka Therapeutics Inc. Common Stock — how do they compare? Healthcare Realty Trust Incorporated Common Stock trades at $17 (market cap $5.90B), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B). The key difference: Healthcare Realty Trust Incorporated Common Stock and Oruka Therapeutics Inc. Common Stock are close in size by market cap, and Healthcare Realty Trust Incorporated Common Stock pays a 5.57% dividend while Oruka Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Healthcare Realty Trust Incorporated Common Stock for 0 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.
| HR | ORKA | |
|---|---|---|
Market Cap | $5.90B | $5.18B |
Volume | 4,466,610 | 490,798 |
Sector | Real Estate | Health |
52-Week High | $21.87 | $113.08 |
52-Week Low | $16.34 | $26.19 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $10.29B | $4.31B |
Dividend Yield | 5.57% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Healthcare Realty Trust Incorporated Common Stock
Healthcare Realty Trust Incorporated is a real estate investment trust that owns and manages outpatient medical facilities and on-campus medical office buildings across US, leasing space to physician groups, hospitals, and health systems.
Read more on HR →About Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →
